FDMT
4D Molecular Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-1.04 EPS, $3.79M rev
Last earnings -4.7% on 2026-05-07
$11.52
▼ -0.86%$11.52▲ +181.66%
over 1Y
L $3.71EODHDH $12.27
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.9%
1W+23.4%
1M+33.4%
3M+17.6%
YTD+58.7%
1Y+184.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Buy
Revenue grew 230194.6% YoY; but unprofitable (net margin -164.4%).
4D Molecular Therapeutics, Inc. shows $85.2M in FY2025 revenue (+230194.6% YoY), a -164.4% net margin, and -27.7% ROE.
Sources: SEC EDGAR (CIK 0001650648, latest 10-Q filed 2026-05-07) · EODHD · as of 6/25/2026, 9:51:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.